OncoMatch/Clinical Trials/NCT03696680
Stereotactic Radiotherapy for Cerebral Metastases with Recent Hemorrhagic Signal
Is NCT03696680 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies non-drug interventions for hemorrhagic brain metastases.
This prospective 2-stage, non-randomized Phase 2 trial evaluates the safety and efficacy of FSRT for the management of hemorrhagic brain metastases
Check if I qualifyExtracted eligibility criteria
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: cerebral stereotactic irradiation
Patient with prior cerebral stereotactic irradiation
Cannot have received: total brain irradiation
History of total brain irradiation
Lab requirements
Blood counts
Thrombocytopenia less than 100,000 cells / mm3 [excluded]
Thrombocytopenia less than 100,000 cells / mm3
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT03696680 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior cerebral stereotactic irradiation, total brain irradiation disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify